BioMarin Pharmaceutical (NASDAQ:BMRN): 15 Analyst have given the stock of BioMarin Pharmaceutical (NASDAQ:BMRN) a near short term price target of $111.8. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $12.35. The higher price target estimate is at $150 while the lower price estimates are fixed at $99.
Many analysts have stated their opinion on the company shares. BMO Capital initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN). The rating major has initiated the coverage with outperform rating on the shares. The rating by the firm was issued on April 7, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Spiegelman Daniel K, officer (EVP, Chief Financial Officer) of Biomarin Pharmaceutical Inc, unloaded 1,649 shares at an average price of $89.14 on June 6, 2016. The total amount of the transaction was worth $146,992, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
BioMarin Pharmaceutical (NASDAQ:BMRN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.99 points or 1.22% at $80.11 with 1,253,238 shares getting traded. Post opening the session at $81.09, the shares hit an intraday low of $79.505 and an intraday high of $83.9799 and the price was in this range throughout the day. The company has a market cap of $13,004 million and the number of outstanding shares have been calculated to be 162,322,440 shares. The 52-week high of BioMarin Pharmaceutical (NASDAQ:BMRN) is $151.75 and the 52-week low is $62.12.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).